Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study

• Jason Aldred,
• Eric Freire-Alvarez,
• Alexander V. Amelin,
• Angelo Antonini,
• Bruno Bergmans,
• Filip Bergquist,
• Manon Bouchard,
• Kumar Budur,
• Camille Carroll,
• K. Ray Chaudhuri,
• Susan R. Criswell,
• Erik H. Danielsen,
• Florin Gandor,
• Jia Jia,
• Thomas E. Kimber,
• Hideki Mochizuki,
• Weining Z. Robieson,
• Amy M. Spiegel,
• David G. Standaert,
• Saritha Talapala,
• Maurizio F. Facheris,
• Victor S. C. Fung

Affiliations

Jason Aldred

Selkirk Neurology and Inland Northwest Research

Eric Freire-Alvarez

Neurology Department, University General Hospital of Elche

Alexander V. Amelin

Department of Neurology and Neurosurgery, Pavlov First Saint Petersburg State Medical University

Angelo Antonini

Parkinson and Movement Disorders Unit, Department of Neuroscience, Padua University

Bruno Bergmans

Department of Neurology, AZ St-Jan Brugge-Oostende AV

Filip Bergquist

Department of Pharmacology, University of Gothenburg

Manon Bouchard

Clinique Neuro-Lévis

Kumar Budur

AbbVie Inc.

Camille Carroll

Faculty of Health, University of Plymouth

K. Ray Chaudhuri

Parkinson’s Foundation International Centre of Excellence, King’s College Hospital

Susan R. Criswell

Department of Neurology, Washington University in St. Louis

Erik H. Danielsen

Department of Neurology, Aarhus University Hospital

Florin Gandor

Movement Disorders Hospital

Jia Jia

AbbVie Inc.

Thomas E. Kimber

Department of Neurology, Royal Adelaide Hospital

Hideki Mochizuki

Department of Neurology, Osaka University Graduate School of Medicine

Weining Z. Robieson

AbbVie Inc.

Amy M. Spiegel

AbbVie Inc.

David G. Standaert

Department of Neurology, Heersink School of Medicine, University of Alabama at Birmingham

Saritha Talapala

AbbVie Inc.

Maurizio F. Facheris

AbbVie Inc.

Victor S. C. Fung

Movement Disorders Unit, Westmead Hospital